Stock 600976 JIANMIN PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jianmin Pharmaceutical Group Co.,Ltd.

Equities

600976

CNE000001HB7

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
62.38 CNY -2.90% Intraday chart for Jianmin Pharmaceutical Group Co.,Ltd. -3.90% -4.40%
Apr. 19 Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Jianmin Pharma Gets Nod to Market Asthma Drug MT

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
  • The group's high margin levels account for strong profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANMIN PHARMACEUTICAL GROUP CO.,LTD. Stock Jianmin Pharmaceutical Group Co.,Ltd.
-4.40% 1.31B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.88% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600976 Stock
  4. Ratings Jianmin Pharmaceutical Group Co.,Ltd.